FATE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.24 USD | +0.47% |
|
+14.59% | +13.37% |
| 10/05 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
| 10/05 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FATE THERAPEUTICS, INC. | Bio Therapeutic Drugs | +0.47% | +14.59% | +13.37% | -20.45% | -76.92% | 48Cr |  |  |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- FATE Stock
- Charts Fate Therapeutics, Inc.
- Comparison Chart
